Zivo Bioscience (ZIVO) AI Stock Analysis

• Market Cap: $27.22M
• Dividend Yield: N/A
• Average Volume (3M): 586.00
• Price to Earnings (P/E): ―
• Beta (1Y): 1.40
• Revenue Growth: 164.52%
• EPS Growth: 53.47%
• Country: US
• Employees: 7
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -4.35
• Shares Outstanding: 3,888,595
• 10 Day Avg. Volume: 232
• 30 Day Avg. Volume: 586
• PEG Ratio: 0.37
• Price to Book (P/B): -142.41
• Price to Sales (P/S): 466.38
• P/FCF Ratio: -17.00
• Enterprise Value/Market Cap: 2.26
• Enterprise Value/Revenue: 293.80
• Enterprise Value/Gross Profit: 927.53
• Enterprise Value/Ebitda: -7.26
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 1
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 34 Underperform
• Price Target: ―

Zivo Bioscience faces significant financial challenges, including negative equity and cash flow issues, which are the primary factors in its low score. Despite some technical indicators showing neutrality, the company's negative valuation metrics further impact the score. Urgent financial restructuring is necessary for sustainability.

Positive Factors

Revenue Growth

The significant revenue growth trajectory indicates strong demand for Zivo's algal bioactive compounds, supporting long-term market potential and business expansion.

Business Model

The licensing and partnership-based business model allows Zivo to leverage its intellectual property, providing scalable revenue streams and reducing operational risks.

Market Position

Operating across multiple high-growth sectors diversifies Zivo's market exposure, enhancing resilience against sector-specific downturns and supporting sustainable growth.

Negative Factors

Financial Instability

Negative equity and insolvency highlight severe financial instability, threatening Zivo's operational continuity and necessitating immediate restructuring for long-term viability.

Cash Flow Issues

Persistent negative cash flow undermines liquidity and limits Zivo's ability to invest in growth opportunities, posing a significant risk to its financial health and strategic initiatives.

Profitability Challenges

Ongoing net losses and negative profit margins indicate operational inefficiencies and a lack of profitability, challenging Zivo's ability to achieve sustainable financial performance.

Zivo Bioscience Business Overview & Revenue Model

Company Description

ZIVO Bioscience, Inc., a research and development company, engages in licensing and selling natural bioactive ingredients derived from its proprietary algae cultures to animal, human, and dietary supplement and medical food manufacturers. The company operates in the biotech and agtech sectors, with an intellectual property portfolio comprising proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques, and patented or patent-pending inventions for applications in human and animal health. Its products indications include poultry gut health, bovine mastitis, canine joint health, human immune modification, algal biomass for human consumption, and biomass for supporting skin health / anti-aging. The company was formerly known as Health Enhancement Products, Inc. and changed its name to ZIVO Bioscience, Inc. in October 2014. ZIVO Bioscience, Inc. is headquartered in Bloomfield Hills, Michigan.

How the Company Makes Money

Zivo Bioscience makes money by developing and licensing its proprietary algal bioactive compounds to companies in the nutrition, wellness, and animal health industries. The company's revenue streams largely consist of licensing fees, royalties, and collaborative research agreements. Through partnerships with manufacturers and distributors, Zivo capitalizes on its intellectual property by integrating its algal compounds into various consumer and animal products. The company may also engage in direct sales of its algal biomass or extracts to businesses looking to include these components in their product offerings. Key partnerships in these sectors help Zivo expand its market reach and contribute to its earnings.

Zivo Bioscience Financial Statement Overview

Summary

Zivo Bioscience is experiencing growth in revenue but is struggling with significant net losses and negative cash flows, indicating financial instability. The balance sheet reflects insolvency with negative equity, requiring urgent financial restructuring. The biotech industry is inherently risky, and the company needs to address its financial challenges to achieve sustainability.

Income Statement

Zivo Bioscience has shown revenue growth over the years, with a TTM revenue of $79,020 compared to $27,650 in the previous year, indicating a significant growth trajectory. However, the company continues to report substantial net losses, resulting in a negative net profit margin. The EBIT and EBITDA margins are negative, reflecting ongoing operational challenges and a lack of profitability.

Balance Sheet

The company's balance sheet is weak with a negative stockholders' equity, indicating insolvency. The debt-to-equity ratio cannot be accurately calculated due to negative equity. The equity ratio is negative due to liabilities exceeding assets, highlighting significant financial risk.

Cash Flow

Zivo Bioscience's cash flow statement reveals a consistent pattern of negative free cash flow, impacting liquidity. The operating cash flow to net income ratio is negative, showing poor cash generation relative to net losses. Although financing activities have provided some cash inflow, it is insufficient to cover operating cash outflows.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	209.03K	157.22K	27.65K	0.00	0.00	20.00K
Gross Profit	66.21K	48.95K	11.61K	0.00	0.00	20.00K
EBITDA	-8.46M	-13.36M	-7.26M	-8.73M	-9.05M	-550.05K
Net Income	-8.49M	-13.38M	-7.78M	-8.75M	-9.40M	-9.66M
Balance Sheet
Total Assets	559.45K	1.64M	555.72K	2.12M	8.99M	220.18K
Cash, Cash Equivalents and Short-Term Investments	57.22K	1.54M	274.38K	1.80M	8.90M	137.86K
Total Debt	432.30K	254.36K	346.34K	445.18K	255.18K	5.36M
Total Liabilities	231.79K	2.16M	2.76M	2.13M	2.95M	11.53M
Stockholders Equity	-3.29M	-514.90K	-2.21M	-10.62K	6.04M	-11.31M
Cash Flow
Free Cash Flow	-3.08M	-4.31M	-5.80M	-7.10M	-6.80M	-2.59M
Operating Cash Flow	-3.08M	-4.31M	-5.80M	-7.10M	-6.80M	-2.59M
Investing Cash Flow	0.00	0.00	0.00	0.00	0.00	0.00
Financing Cash Flow	2.98M	5.58M	4.28M	-628.60K	15.57M	2.38M

Zivo Bioscience Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 7.54
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ZIVO, the sentiment is Negative. The current price of 7.54 is below the 20-day moving average (MA) of 8.95, below the 50-day MA of 10.15, and below the 200-day MA of 13.76, indicating a bearish trend. The MACD of -0.50 indicates Positive momentum. The RSI at 40.76 is Neutral, neither overbought nor oversold. The STOCH value of 26.17 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ZIVO.

Zivo Bioscience Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
JSPR	52 Neutral	$41.42M	-0.26	-191.12%	―	―	-24.38%
IPSC	52 Neutral	$178.31M	-6.92	-14.23%	―	4121.12%	83.30%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
RNXT	51 Neutral	$38.48M	-2.94	-146.61%	―	―	37.89%
NRSN	44 Neutral	$30.59M	-1.87	―	―	―	31.09%
MDCX	43 Neutral	$36.67M	-0.69	-2237.54%	―	―	-55.95%
ZIVO	34 Underperform	$27.22M	-3.33	657.30%	―	164.52%	53.47%

Zivo Bioscience Corporate Events

Zivo Bioscience CFO Resigns, Interim Successor Appointed

On December 19, 2025, Zivo Bioscience’s Chief Financial Officer, Keith R. Marchiando, resigned effective immediately and agreed to end his employment with the company on December 31, 2025, under a separation agreement that provides him with his current monthly salary of $27,040 through December 31, 2026 and allows him to retain previously granted stock options to purchase 150,000 shares at $7.96 per share exercisable until June 30, 2027, alongside standard release, confidentiality and non-disparagement provisions. To maintain continuity in its finance function, the company appointed veteran biotech finance executive William A. Sullivan, 54, as Interim Chief Financial Officer effective December 19, 2026, under an independent contractor services agreement paying $285 per hour for an initial 60-day term with automatic month-to-month renewals and restrictions on solicitation and business diversion, signaling Zivo’s reliance on specialized life sciences financial expertise during this management transition.